Treatment & Procedure
CPAP for sleep apnea
Biohacking
With CPAP, you sleep with a breathing mask that keeps the upper airways open with slight positive pressure. Against the nightly breathing pauses, this works reliably and immediately. As heart protection it is not proven: in the largest randomized trial on the question, SAVE, the device did not prevent heart attacks or strokes.
In short
In SAVE (NEJM 2016), the apnea-hypopnea index under CPAP fell from 29 to 3.7 events per hour, almost ninety percent fewer. Snoring, daytime sleepiness, health-related quality of life and mood improved significantly. The hard endpoint did not materialize: in 2,717 adults aged 45 to 75 with moderate to severe sleep apnea and pre-existing cardiovascular disease, the hazard ratio for serious cardiovascular events after 3.7 years was 1.1 (95% CI 0.91–1.32). That speaks not against the device, but against marketing it as heart protection.
What CPAP is and how it works
CPAP stands for “continuous positive airway pressure”, a steady positive pressure in the airways. A small device next to the bed blows air at an even, slight positive pressure through a tube and mask into the nose or mouth. This pressure keeps the upper airways open during sleep, so that they no longer collapse and breathing no longer stalls.
The effect is measured with the apnea-hypopnea index, the number of breathing pauses and phases of too-shallow breathing per hour of sleep. The treatment works without medication, takes effect from the first night and can be stopped at any time. Sleep apnea is associated with an increased risk of cardiovascular events. This gave rise to the expectation that eliminating the breathing pauses would also protect the heart and blood vessels. SAVE tested exactly this expectation.
What is well supported
That the device works is undisputed. In SAVE, the apnea-hypopnea index fell from 29.0 to 3.7 events per hour, meaning almost ninety percent fewer breathing pauses. In the same study, snoring, daytime sleepiness, health-related quality of life and mood improved significantly compared with the group without the device.
This matches what users report: less snoring, more alert during the day, better mood. Here user reports and measured endpoints agree, which is rare in this field.
What the studies show
McEvoy 2016 — SAVE, randomized
After a one-week run-in phase with sham CPAP, 2,717 adults aged 45 to 75 with moderate to severe obstructive sleep apnea and established coronary or cerebrovascular disease were randomized: CPAP plus usual care or usual care alone. The primary endpoint was a composite of cardiovascular death, heart attack, stroke and hospitalization for unstable angina, heart failure or transient ischemic attack.
After a mean of 3.7 years, such an event occurred in 229 participants in the CPAP group (17.0 percent) and in 207 in the comparison group (15.4 percent). The hazard ratio was 1.10 (95% CI 0.91–1.32; p = 0.34). CPAP also had no significant effect on any individual or other composite cardiovascular endpoint. The secondary endpoints snoring, daytime sleepiness, quality of life and mood, by contrast, improved significantly. On average, participants used the device 3.3 hours per night.
Where the data stop
SAVE is a textbook case of the difference between surrogate and outcome. The measured value, the number of breathing pauses, fell drastically. The outcome that ultimately matters, fewer heart attacks and strokes, did not materialize.
The study has limits worth knowing. It examined people who already had cardiovascular disease; for people without prior disease, SAVE says nothing. Most participants were men with moderate to severe sleep apnea and only mild daytime sleepiness. And at a mean of 3.3 hours per night, the device covered only part of sleep. Whether longer nightly use changes anything for the heart is not answered by the main analysis.
User reports also reach their limit here: they confirm what people feel, that is, sleep and alertness. They cannot say anything about the heart, and that is exactly where the gap lies.
Status, approval and legal
CPAP is a medical treatment for sleep apnea, not a lifestyle device. Diagnosis and setup belong in a sleep laboratory. The therapy is proven for what it directly treats: the breathing pauses and their consequences for sleep, alertness and well-being. Anyone who markets CPAP as protection against heart attack or stroke is, after SAVE, not relying on data.
Safety
The safety data are good: CPAP has long been in wide use and in SAVE was followed in more than 2,700 people over a mean of 3.7 years. The treatment works without medication and can be stopped at any time. The slightly higher event rate in the CPAP group (17.0 vs. 15.4 percent) was not statistically significant and is no indication of harm, but it does indicate that no heart protection was measurable. The axis rates the data, not the danger.
BK-Score Well supported, heavily overhyped
| Human evidence | 9 | |
|---|---|---|
| Mechanism | 9 | |
| Safety data | 9 | |
| Hype gap | 4 | |
| Track record of use | 9 |
A textbook case of the difference between surrogate and outcome. That the device works is undisputed: in SAVE (NEJM 2016), the apnea-hypopnea index fell from 29 to 3.7 per hour. Snoring, daytime sleepiness, quality of life and mood improved significantly. The hard endpoint is missing: in 2,717 adults aged 45 to 75 with moderate to severe sleep apnea and pre-existing cardiovascular disease, the hazard ratio for cardiac death, heart attack and stroke after 3.7 years was 1.1 (95% CI 0.91–1.32; p = 0.34). The hype deduction applies to the marketing as heart protection, not to the device.
The score rates the state of knowledge, not the substance. “Safety data 9” means well studied – not harmless. “Track record of use 9” means used long and widely – that is not proof of efficacy.
Subjective assessment by Biohacking Kompakt based on published scoring rules – not a scientific rating and not a medical recommendation. Rules and all ratings (German)
Frequently asked questions about CPAP for sleep apnea
What does CPAP do for sleep apnea?
It strongly reduces the breathing pauses: in the SAVE study, their number fell from 29 to 3.7 per hour. Snoring, daytime sleepiness, quality of life and mood improved demonstrably.
Does CPAP protect against heart attack and stroke?
Not in the largest randomized trial. In 2,717 people with sleep apnea and established cardiovascular disease, SAVE found no difference after 3.7 years; the hazard ratio was 1.1.
Is CPAP useless after the SAVE study?
No. The proven effects on snoring, daytime sleepiness, quality of life and mood remain. SAVE only shows that no protection against cardiovascular events can be derived from them.
How long did the participants use the device?
On average 3.3 hours per night. Whether longer use would change anything for the heart is not answered by the main analysis of the study.
Does the result also apply to people without heart disease?
SAVE says nothing about that. It studied adults aged 45 to 75 who already had coronary or cerebrovascular disease, mostly men with little daytime sleepiness.
Related
- Related topicChelation therapy
- Related topicSleep & sleep hygiene
- Same sectionOral microbiome & periodontitis
- Same sectionLipoprotein(a)
- Same sectionSauna & cold (hormesis)
- Same sectionVNS analysis (HRV)
Sources
Open in the database – with search, filters and comparison (German app)
Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Last updated: 2026-10-05.